NDC 50222-346
Adbry
Tralokinumab-ldrm
Adbry is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Leo Pharma Inc.. The primary component is Tralokinumab.
| Product ID | 50222-346_078bc388-36dc-4b6e-bb32-ccdafcc39128 |
| NDC | 50222-346 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Adbry |
| Generic Name | Tralokinumab-ldrm |
| Dosage Form | Injection, Solution |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2022-01-02 |
| Marketing Category | BLA / |
| Application Number | BLA761180 |
| Labeler Name | LEO Pharma Inc. |
| Substance Name | TRALOKINUMAB |
| Active Ingredient Strength | 150 mg/mL |
| Pharm Classes | Interleukin-13 Antagonist [EPC], Interleukin-13 Antagonists [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
Packaging
NDC 50222-346-02
2 SYRINGE, GLASS in 1 CARTON (50222-346-02) > 1 mL in 1 SYRINGE, GLASS (50222-346-01)
| Marketing Start Date | 2022-01-02 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Drug Details
Trademark Results [Adbry]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 ADBRY 90803235 not registered Live/Pending |
LEO Pharma A/S 2021-06-30 |
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.